← Issue №11/ week of Sep 13, 2026/Endoscopy

A prospective clinical trial of eus-shear wave measurement of liver and spleen for hepatic fibrosis.

From GI Signals issue №11: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Endoscopy prospective cohort · n=109 · Sep 9, 2026 · GIE · IF 8.0

A prospective clinical trial of eus-shear wave measurement of liver and spleen for hepatic fibrosis.

DiagnosticcirrhosisEUSbiomarker
Clinical takeawayFor EUS patients undergoing the procedure and requiring cirrhosis assessment, perform right-lobe and splenic shear wave stiffness measurement using standard transducer pressure. Splenic measurement is highly accurate for cirrhosis detection (AUC 0.962), outperforming APRI and FIB4. Do not rely on EUS-SWM for intermediate fibrosis staging (F2-F3).
What it foundSplenic shear wave stiffness via EUS identified cirrhosis with AUC 0.962, outperforming APRI and FIB4; hepatic stiffness correlated strongly with histologic fibrosis (left lobe r=0.837-0.872, right lobe r=0.748-0.766).
ContextRefines non-invasive cirrhosis detection for the subset of patients already undergoing EUS, with superior accuracy compared to serology-based APRI and FIB4 scores. No head-to-head comparison with transient elastography, the current standard non-invasive test, so relative positioning unclear.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Kohli DR … Srikureja W · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
← Read the whole of issue №11 Every paper GI Signals surfaces gets a page like this one. All issues